Apimeds Pharmaceuticals US, Inc.
APUS· NYSE
Released May 19, 2025, after the close
10-Q filed May 20, 2025, 50 days after period end · 0001213900-25-045588
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Income | -$402.40K | -$296.47K |
| EPS Diluted | -$0.05 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Apimeds Pharmaceuticals US, Inc. · CIK 1894525 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 20, 2025 · 50 d after period end
+2.9% from the close of May 16, 2025 to the close of May 22, 2025, the first after the release.